此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

研究概览

研究类型

介入性

注册 (估计的)

38

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35222
        • Alabama (Site ID: 31788)
        • 接触:
    • California
      • Los Angeles、California、美国、90035
        • University of California, Los Angeles CARE Center (Site ID: 601)
        • 接触:
      • San Diego、California、美国、92103
        • UCSD Antiviral Research Center (Site ID: 701)
        • 接触:
      • San Francisco、California、美国、94110
        • University of California, San Francisco (Site ID: 801)
        • 接触:
      • Torrance、California、美国、90502-2052
        • Harbor University of California Los Angeles Center (Site ID: 603)
        • 接触:
    • Colorado
      • Aurora、Colorado、美国、80045
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20032
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University (Site ID: 2701)
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins University (Site ID: 201)
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital (Site ID: 101)
        • 接触:
      • Boston、Massachusetts、美国、02115
        • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
        • 接触:
    • New Jersey
      • Newark、New Jersey、美国、07103
        • New Jersey Medical School Clinical Research Center (Site ID: 31786)
        • 接触:
    • New York
      • New York、New York、美国、10010
        • Weill Cornell Chelsea (Site ID: 7804)
        • 接触:
      • New York、New York、美国、10010
        • Weill Cornell Uptown (Site ID: 7803)
        • 接触:
      • New York、New York、美国、10032
        • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
        • 接触:
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599-7215
        • Chapel Hill (Site ID: 3201)
        • 接触:
      • Greensboro、North Carolina、美国、27401-1020
    • Ohio
      • Cincinnati、Ohio、美国、45267-0405
        • Cincinnati Clinical Research Site (Site ID: 2401)
        • 接触:
      • Cleveland、Ohio、美国、44106
      • Columbus、Ohio、美国、43210
        • Ohio State University (Site ID: 2301)
        • 接触:
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh (Site ID: 1001)
        • 接触:
    • Tennessee
      • Nashville、Tennessee、美国、37204
        • Vanderbilt Therapeutics (VT) (Site ID: 3652)
        • 接触:
    • Texas
      • Houston、Texas、美国、77030
        • Houston Advancing Research Team (Site ID: 31473)
        • 接触:
    • Washington
      • Seattle、Washington、美国、98104
        • University of Washington Positive Research (Site ID: 1401)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Documented HIV-1 infection

  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use

  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry

  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence

  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance

  • Adequate laboratory parameters within 60 days prior to study entry:

    • Absolute neutrophil count >600/mm3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count >50,000/μL
    • AST and ALT ≤3 × upper limit of normal
    • Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry

  • Ability and willingness to provide informed consent

  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Child-Pugh Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 48
Baseline through Week 48

次要结果测量

结果测量
措施说明
大体时间
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 48
Week 48
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 48
Week 48
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 48
Week 48
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 96
Baseline through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
大体时间:Baseline through Week 96
Baseline through Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 96
Baseline through Week 96
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 96
Week 96
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 96
Week 96
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 96
Week 96
Percentage of on-time long-acting injections
大体时间:Through Week 48 and through Week 96
Through Week 48 and through Week 96
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
大体时间:Baseline through Week 48 and through Week 96
Baseline through Week 48 and through Week 96
Plasma trough concentrations of lenacapavir and cabotegravir
大体时间:Through Week 48 and through Week 96
Through Week 48 and through Week 96
Change in CD4 cell count from baseline
大体时间:Week 48 and Week 96
Week 48 and Week 96
Participant-reported treatment satisfaction
大体时间:Week 48 and Week 96

HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

Week 48 and Week 96
Change in quality-of-life scores from baseline
大体时间:Week 48 and Week 96

Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

Week 48 and Week 96
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
大体时间:Week 48 and Week 96

Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Week 48 and Week 96
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
大体时间:Baseline through Week 48
Baseline through Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
大体时间:Week 48
Week 48
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
大体时间:Week 48
Week 48
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
大体时间:Week 48
Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2028年2月1日

初级完成 (估计的)

2029年8月31日

研究完成 (估计的)

2030年10月26日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Individual participant data that underlie results in the publication after deidentification

IPD 共享时间框架

Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

IPD 共享访问标准

With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.

For what types of analyses? To achieve aims in the proposal approved by the ACTG.

By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅